{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:55:40Z","timestamp":1788357340237,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.anai.2026.03.026","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T23:56:52Z","timestamp":1775260612000},"page":"64-71.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Five-year inhaled, systemic, and total corticosteroid exposure reduction during anti\u2012interleukin-5 receptor alpha treatment for severe asthma"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5804-0740","authenticated-orcid":false,"given":"Kjell Erik Julius","family":"H\u00e5kansson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne Baastrup","family":"Soendergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asger","family":"Sverrild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"von B\u00fclow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Hilberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Silberbrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Lock-Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lycely","family":"Dongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Vijdea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Makowska","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes Martin","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte Suppli","family":"Ulrik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sofie","family":"Bjerrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Porsbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10516","key":"10.1016\/j.anai.2026.03.026_bib0001","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/S0140-6736(25)01625-3","article-title":"Anti-cytokine biologics for asthma in adults","volume":"406","author":"Israel","year":"2025","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.anai.2026.03.026_bib0002","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jaip.2024.12.010","article-title":"Systemic corticosteroids: the importance of limiting their use in asthma","volume":"13","author":"Fuhlbrigge","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2026.03.026_bib0003","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/bcpt.13680","article-title":"Changes in oral corticosteroid use in asthma treatment - a 20-year Danish nationwide drug utilization study","volume":"130","author":"Skov","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"11","key":"10.1016\/j.anai.2026.03.026_bib0004","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.anai.2026.03.026_bib0005","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00703-2018","article-title":"Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature","volume":"52","author":"Volmer","year":"2018","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.anai.2026.03.026_bib0006","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03054-2021","article-title":"Low dose oral corticosteroids in asthma associates with increased morbidity and mortality","volume":"60","author":"Skov","year":"2022","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.anai.2026.03.026_bib0007","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jaip.2024.10.024","article-title":"Longitudinal assessment of glucocorticoid toxicity reduction in patients with severe asthma treated with biologic therapies","volume":"13","author":"McDowell","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2026.03.026_bib0008","doi-asserted-by":"crossref","first-page":"00677","DOI":"10.1183\/23120541.00677-2025","article-title":"Cumulative corticosteroid burden over twenty-five years in patients initiating biologic therapy for severe asthma \u2013 a nationwide cohort study","volume":"12","author":"Berner","year":"2026","journal-title":"ERJ Open Res"},{"issue":"2","key":"10.1016\/j.anai.2026.03.026_bib0009","doi-asserted-by":"crossref","first-page":"00625","DOI":"10.1183\/23120541.00625-2024","article-title":"Effectiveness of anti-IL-5\/5R\u03b1 biologics in severe asthma in real-world studies: a systematic review and meta-analysis","volume":"11","author":"Kyriakopoulos","year":"2025","journal-title":"ERJ Open Res"},{"issue":"25","key":"10.1016\/j.anai.2026.03.026_bib0010","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid\u2013sparing effect of Benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.anai.2026.03.026_bib0011","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.anai.2026.03.026_bib0012","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.chest.2023.10.046","article-title":"Clinical response and remission in severe asthma patients treated with biologic therapies","volume":"165","author":"Hansen","year":"2024","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.anai.2026.03.026_bib0013","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2026.03.026_bib0014","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00408-025-00796-5","article-title":"Supratherapeutic inhaled corticosteroid use in patients initiating on biologic therapies for severe asthma: a nationwide cohort study","volume":"203","author":"Hjortdahl","year":"2025","journal-title":"Lung"},{"issue":"1","key":"10.1016\/j.anai.2026.03.026_bib0015","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01147-2019","article-title":"Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma","volume":"55","author":"Maijers","year":"2020","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.anai.2026.03.026_bib0016","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jaip.2025.01.023","article-title":"Use of high-dose inhaled corticosteroids and risk of corticosteroid related adverse events in asthma -findings from the NORDSTAR cohort","volume":"13","author":"von B\u00fclow","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2026.03.026_bib0017","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1164\/rccm.202402-0368OC","article-title":"Association of dose of inhaled corticosteroids and frequency of adverse events","volume":"211","author":"Bloom","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.anai.2026.03.026_bib0018","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","article-title":"Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma","volume":"34","author":"Holgate","year":"2004","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"10.1016\/j.anai.2026.03.026_bib0019","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.jaip.2023.03.009","article-title":"Severe asthma standard-of-care background medication reduction with Benralizumab: ANDHI in practice substudy","volume":"11","author":"Louis","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10423","key":"10.1016\/j.anai.2026.03.026_bib0020","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(23)02284-5","article-title":"Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study","volume":"403","author":"Jackson","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.anai.2026.03.026_bib0021","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.anai.2026.03.026_bib0022","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S2213-2600(25)00299-1","article-title":"Reframing remission in severe asthma: a conceptual framework for distinguishing disease activity versus damage","volume":"13","author":"Porsbjerg","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2026.03.026_bib0023","doi-asserted-by":"crossref","DOI":"10.1080\/20018525.2020.1842117","article-title":"The Danish severe asthma register: an electronic platform for severe asthma management and research","volume":"8","author":"Hansen","year":"2021","journal-title":"Eur Clin Respir J"},{"key":"10.1016\/j.anai.2026.03.026_bib0024","unstructured":"Medicinr\u00e5det. Medicinr\u00e5dets laegemiddelrekommandation og behandlingsvejledning vedr\u00f8rende biologiske laegemidler til svaer astma. version 2.5. Accessed July 15, 2025. Available at: https:\/\/filer.medicinraadet.dk\/media\/z5ena50t\/medicinradets-laegemiddelrek-og-beh-vejl-vedr-svaer-astma-vers-2-5.pdf"},{"issue":"1","key":"10.1016\/j.anai.2026.03.026_bib0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13223-024-00882-y","article-title":"Real-world association between systemic corticosteroid exposure and complications in US patients with severe asthma","volume":"20","author":"Casale","year":"2024","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"13","key":"10.1016\/j.anai.2026.03.026_bib0026","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2026.03.026_bib0027","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with Benralizumab (PONENTE): a multicentre, open-label, single-arm study","volume":"10","author":"Menzies-Gow","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.anai.2026.03.026_bib0028","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3390\/jcm12030985","article-title":"Effectiveness of Benralizumab in OCS-dependent severe asthma: the impact of 2 years of therapy in a real-life setting","volume":"12","author":"Vitale","year":"2023","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.anai.2026.03.026_bib0029","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.jaip.2022.05.042","article-title":"REALITI-A study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma","volume":"10","author":"Pilette","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"10.1016\/j.anai.2026.03.026_bib0030","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.clinthera.2019.07.007","article-title":"Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX study","volume":"41","author":"Khurana","year":"2019","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.anai.2026.03.026_bib0031","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","article-title":"Long-term safety and efficacy of Benralizumab in patients with severe, uncontrolled asthma: 1-year results from the Bora phase 3 extension trial","volume":"7","author":"Busse","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.anai.2026.03.026_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1449220","article-title":"Long-term effects of mepolizumab in patients with severe eosinophilic asthma: a 6-year real-life experience","volume":"15","author":"Stanziola","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.anai.2026.03.026_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106260","article-title":"Oral corticosteroid sparing effects of anti-IL5\/anti-IL5 receptor treatment after 2 years of treatment","volume":"176","author":"Bjerrum","year":"2021","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.anai.2026.03.026_bib0034","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00926-2025","article-title":"Long-term efficacy but rare sustained remission: individual-level five-year stability in anti-IL5\/R\u03b1 biologic therapy response for severe asthma","volume":"67","author":"H\u00e5kansson","year":"2026","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2026.03.026_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.108198","article-title":"ICS use trajectories in severe asthma patients on Benralizumab: real-life data from 3-years follow-up","volume":"245","author":"Pini","year":"2025","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.anai.2026.03.026_bib0036","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.arbres.2025.08.001","article-title":"Inhaled corticosteroid reduction effects on asthma outcomes after three years of Benralizumab treatment in severe asthma patients","volume":"62","author":"Arteaga","year":"2026","journal-title":"Arch Bronconeumol"},{"issue":"5","key":"10.1016\/j.anai.2026.03.026_bib0037","article-title":"Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma","volume":"55","author":"D\u2019Ancona","year":"2020","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.anai.2026.03.026_bib0038","first-page":"10","article-title":"Prevention of cardiovascular and other systemic adverse outcomes in patients with asthma treated with biologics","volume":"18","author":"Sadatsafavi","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.anai.2026.03.026_bib0039","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/all.16537","article-title":"Head-to-head comparison of biologic efficacy in asthma: what have we learned?","volume":"80","author":"Lipworth","year":"2025","journal-title":"Allergy Eur J Allergy Clin Immunol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626001481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626001481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:17:48Z","timestamp":1782465468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120626001481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1081120626001481"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2026.03.026","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Five-year inhaled, systemic, and total corticosteroid exposure reduction during anti\u2012interleukin-5 receptor alpha treatment for severe asthma","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2026.03.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}